503A vs. 503B Pharmacies Explained

By Alsen Walker · Editorially reviewed on 25 August 2026 · Not medically reviewed by a clinician

The difference is oversight. A 503A pharmacy compounds for individual patients against individual prescriptions and is regulated primarily by state boards of pharmacy. A 503B outsourcing facility registers with FDA, is subject to federal inspection and manufacturing standards, and can produce in larger quantities. For a patient, the second carries more oversight than the first.

For the wider picture on compounded products and how to check a supplier, see Compounded GLP-1s: What They Are and How to Check a Supplier.

503A: traditional compounding

Prepares medications for named patients against valid prescriptions.

Regulated mainly at state level by boards of pharmacy. Not subject to the same federal manufacturing requirements as approved drug manufacturers.

Not required to test every batch to the standard a manufacturer would, and practice varies considerably between pharmacies.

This is the traditional model and it is entirely legitimate for its intended purpose. The question is whether large-volume production of copies of an approved drug is that purpose.

503B: outsourcing facilities

Created under federal legislation following a contamination outbreak that caused deaths and exposed gaps in oversight of large-scale compounding.

Register with FDA, are subject to federal inspection, and must follow current good manufacturing practice requirements.

Can produce without patient-specific prescriptions, which is what allows supply to clinics and telehealth services.

More oversight than 503A, and still not the same as an approved drug manufacturer producing an approved product.

Why it matters to you

If you are using a compounded product, which type of facility made it tells you something meaningful about the manufacturing standards behind it.

Neither status makes a compounded product FDA-approved. Approval applies to products, not to facilities, and no compounded GLP-1 is an approved product.

How to find out which you are dealing with

Ask the provider directly: which pharmacy or facility prepares this, and is it a 503A pharmacy or a 503B outsourcing facility.

FDA publishes a registered outsourcing facility list, and state boards of pharmacy publish licence lookups. Both are public and checkable.

A provider unwilling to name the source is telling you something. Legitimate operations answer this without difficulty.

What neither status guarantees

That the concentration matches what you were told. That the product is stable for the period you will be using it. That the active ingredient is what it claims. That a recall would reach you.

Registration and inspection reduce risk. They do not substitute for approval.

Frequently asked questions

Is 503B safer than 503A?
It carries more federal oversight and manufacturing requirements. Neither produces an FDA-approved product.

How do I check a facility?
FDA publishes a registered outsourcing facility list; state boards publish pharmacy licence lookups.

Does my telehealth provider have to tell me the source?
Ask. Reluctance to answer is itself informative.

Are 503B products FDA-approved?
No. The facility registers with FDA; the product is not approved.

Can a 503A pharmacy make large batches?
Its model is patient-specific compounding. Large-scale production sits outside that purpose.

Does this affect insurance?
No. Compounded GLP-1s are not covered under standard plans regardless of facility type.